ストックスクリーナーアプリを入手
12.09
7.43%
-0.97
アフターアワーズ：
12.20
0.11
+0.91%
前日終値:
$13.06
開ける：
$13.02
24時間の取引高:
1.07M
Relative Volume:
0.98
時価総額：
$1.55B
収益：
当期純損益:
株価収益率:
-5.6092
EPS:
-2.1554
ネットキャッシュフロー:
1週間 パフォーマンス:
-15.69%
1か月 パフォーマンス:
-22.90%
6か月 パフォーマンス:
-4.12%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$11.84
$13.22
1週間の範囲:
$11.84
$14.37
52週間の値動き範囲:
$11.00
$22.67
Generate Biomedicines Inc Stock (GENB) Company Profile
名前
Generate Biomedicines Inc
セクター
電話
888-469-0055
住所
101 SOUTH STREET, SUITE 900, SOMERVILLE
Compare GENB vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
12.09 | 1.55B | 0 | 0 | 0 | -2.1554 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-13 | 開始されました | H.C. Wainwright | Buy |
| 2026-03-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2026-03-24 | 開始されました | Goldman | Buy |
| 2026-03-24 | 開始されました | Guggenheim | Buy |
| 2026-03-24 | 開始されました | Morgan Stanley | Overweight |
| 2026-03-24 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Generate Biomedicines Inc (GENB) 最新ニュース
Pharmaceutical Market Research: Global Industry to Reach USD 3.22 Trillion by 2035 as Biologics, AI-Driven Drug Discovery, and Manufacturing Investments Reshape Competition - GlobeNewswire Inc.
An ovarian cancer trial tests cell therapy without chemotherapy beforehand. Its first patient has been dosed. - Stock Titan
Generate Biomedicines (NasdaqGS:GENB) Stock Forecast & Analyst Predictions - Simply Wall Street
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
Generate Biomedicines (NasdaqGS:GENB) Stock Price - Simply Wall Street
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to S&P Global BMI Index - marketscreener.com
Generate Biomedicines (GENB) Slips 3.15% as Shares Test Support Near $15Max Pain Level - dars.gov.et
Generate Biomedicines at Cantor healthcare conference: pipeline gains traction By Investing.com - Investing.com South Africa
Generate Biomedicines at Cantor healthcare conference: pipeline gains traction By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy on Generate Biomedicines stock By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Buy on Generate Biomedicines stock By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy on Generate Biomedicines stock By Investing.com - Investing.com India
Generate Biomedicines (GENB) Slips 3% as Shares Test Key Support at $15.11Imbalance Zone - dars.gov.et
Generate Biomedicines to Present at Upcoming Investor Conferences - Quiver Quantitative
Generate Biomedicines Inc. to Participate in September Investor Conferences - marketscreener.com
Five September talks will stream online from Generate Biomedicines - Stock Titan
Director at Generate Biomedicines (GENB) sells 1,000 shares near $16 - Stock Titan
Frances Arnold plans 2026 stock sale in Generate Biomedicines (NASDAQ: GENB) - Stock Titan
Director at Generate Biomedicines (GENB) lines up a major stock sale - Stock Titan
Generate Biomedicines stock price target raised to $30 by H.C. Wainwright on asthma data - Investing.com UK
H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Generate Biomedicines Is Maintained at Buy by HC Wainwright & Co. - Moomoo
Companies Like Generate Biomedicines (NASDAQ:GENB) Are In A Position To Invest In Growth - simplywall.st
Nvidia GPUs Are Table Stakes in AI Drug Discovery, Generate Biomedicines CTO Says - finance.biggo.com
Generate Biomedicines Reports Premature Release of GB-0895 Clinical Posters Ahead of ERS Congress 2026 - Kalkine Media
Certain Warrants of Generate Biomedicines, Inc. are subject to a Lock-Up Agreement Ending on 26-AUG-2026. - marketscreener.com
Generate Biomedicines shares jump 20% ahead of post-IPO lock-up expiry - Pluang
Nvidia backs Generate Biomedicines in AI drug discovery push - scanx.trade
102,450,201 Common Stock of Generate Biomedicines, Inc. are subject to a Lock-Up Agreement Ending on 26-AUG-2026. - marketscreener.com
Certain Stock Options of Generate Biomedicines, Inc. are subject to a Lock-Up Agreement Ending on 26-AUG-2026. - www.marketscreener.com
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Generate Biomedicines Inc (NASDAQ:GENB) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Generate Biomedicines Inc's (NASDAQ:GENB) Lock-Up Period To End on August 26th - MarketBeat
8 Stocks Nvidia Has Invested InU.S. News - U.S. News - Money
Generate Biomedicines (NASDAQ:GENB) Shares Up 4.9%Still a Buy? - MarketBeat
Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Q3 EPS Estimate for Generate Biomedicines Lowered by Analyst - MarketBeat
Generate Biomedicines (NASDAQ:GENB) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Generate Biomedicines Shares Fall Following Q2 Financial Results - marketscreener.com
Generate Biomedicines Shares Fall Following Q2 Financial Results - Yahoo Finance
Earnings Flash (GENB) Generate Biomedicines Inc. Reports Q2 Revenue $6.3M - marketscreener.com
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business ... - Caledonian Record
Press Release: Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
Generate Biomedicines: Q2 Earnings Snapshot - marketscreener.com
Generate Biomedicines: Q2 Earnings Snapshot - AOL.com
Generate Biomedicines reports Q2 2026: $6.3M revenue, $67.3M net loss, $457.4M cash - TradingView
Generate Biomedicines, Inc. Q2 2026: Revenue $6.3M, EPS $(0.52) — 10-Q Summary - TradingView
GENB: Phase 3 clinical and AI-driven pipeline progress offset by rising R&D costs and net loss - TradingView
Generate Biomedicines Inc (GENB) 財務データ
収益
当期純利益
現金流量
EPS
Generate Biomedicines Inc (GENB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ARNOLD FRANCES | Director |
Sep 01 '26 |
Proposed Sale |
16.00 |
1,000 |
16,002 |
0 |
| Nally Michael | Chief Executive Officer |
Mar 04 '26 |
Buy |
12.00 |
20,000 |
240,000 |
572,707 |
| Grous Beth | Chief People Officer |
Mar 02 '26 |
Buy |
16.00 |
300 |
4,800 |
300 |
| Silvers Jason | President & CFO |
Mar 02 '26 |
Buy |
16.00 |
2,000 |
32,000 |
1,000 |
| AFEYAN NOUBAR | Director |
Mar 02 '26 |
Buy |
16.00 |
4,687,500 |
75,000,000 |
15,264,724 |
| Mendillo Jane L | Director |
Mar 02 '26 |
Buy |
16.00 |
1,500 |
24,000 |
1,500 |
| AFEYAN NOUBAR | Director |
Mar 02 '26 |
Buy |
16.00 |
4,687,500 |
75,000,000 |
15,264,724 |
1.79%
0.18%
大文字化:
|
ボリューム (24 時間):